Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Anesiva discontinues Zingo, reports results from phase III trial of Adlea

Nov. 12, 2008

Novel agents for psychiatric disorders described in recent patent literature

Nov. 11, 2008

Insmed gains royalty-free worldwide rights for Iplex for ALS

Nov. 11, 2008

GSK and XenoPort plan to withdraw and resubmit Solzira NDA for RLS

Nov. 11, 2008

Azur and Elan sign agreement to develop once-daily clozapine

Nov. 11, 2008

Novel analgesic agents imparted in recent GSK patent

Nov. 10, 2008

Raptor collaborates with Centre Hospitalier Universitaire d'Angers on Huntington's disease trial

Nov. 10, 2008

Sanochemia and Avigen terminate licensing agreement for tolperisone for MS

Nov. 7, 2008

Repligen initiates phase IIb RG-2417 study in bipolar disorder

Nov. 7, 2008

Phase II CERE-110 trial in Alzheimer's disease to be funded by NIH grant

Nov. 6, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 15, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...